Mackenzie Financial Corp Halozyme Therapeutics, Inc. Transaction History

Mackenzie Financial Corp

$63.2 Billion
Q2 2024

A detailed history of Mackenzie Financial Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 14,779 shares of HALO stock, worth $841,072. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,779

Previous 10,386 42.3%

Holding current value

$841,072

Previous $422,000 83.18%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $166,099 - $230,193	4,393 Added 42.3%	14,779 $773,000
Q1 2024 May 10, 2024	BUY	$33.68 - $41.95 $5,489 - $6,837	163 Added 1.59%	10,386 $422,000
Q2 2023 Aug 03, 2023	SELL	$30.28 - $38.74 $76,305 - $97,624	-2,520 Reduced 19.78%	10,223 $368,000
Q1 2023 Apr 24, 2023	SELL	$32.86 - $55.7 $19,913 - $33,754	-606 Reduced 4.54%	12,743 $486,000
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $79,599 - $118,107	1,987 Added 17.49%	13,349 $759,000
Q3 2022 Oct 07, 2022	SELL	$38.53 - $51.78 $1.96 Million - $2.64 Million	-50,894 Reduced 81.75%	11,362 $449,000
Q2 2022 Aug 10, 2022	SELL	$37.35 - $48.3 $545,459 - $705,373	-14,604 Reduced 19.0%	62,256 $2.74 Million
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $118,896 - $152,702	-3,719 Reduced 4.62%	76,860 $3.07 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $16,228 - $20,782	-510 Reduced 0.63%	80,579 $3.24 Million
Q3 2021 Nov 08, 2021	BUY	$38.47 - $46.42 $2.1 Million - $2.54 Million	54,652 Added 206.73%	81,089 $3.3 Million
Q2 2021 Aug 11, 2021	BUY	$38.84 - $51.31 $185,266 - $244,748	4,770 Added 22.02%	26,437 $1.2 Million
Q1 2021 May 14, 2021	BUY	$39.51 - $51.45 $856,063 - $1.11 Million	21,667 New	21,667 $903,000
Q4 2020 Feb 10, 2021	SELL	$25.81 - $43.62 $441,867 - $746,774	-17,120 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $278,558 - $320,655	-10,822 Reduced 38.73%	17,120 $450,000
Q2 2020 Aug 13, 2020	SELL	$16.25 - $26.81 $228,735 - $377,377	-14,076 Reduced 33.5%	27,942 $749,000
Q1 2020 May 14, 2020	BUY	$13.9 - $21.83 $419,891 - $659,440	30,208 Added 255.78%	42,018 $755,000
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $176,323 - $230,649	11,810 New	11,810 $209,000
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $255,664 - $297,545	-16,820 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $234,470 - $295,695	16,820 New	16,820 $271,000

Others Institutions Holding HALO

# of Institutions

488

Shares Held

122M

Call Options Held

208K

Put Options Held

66.3K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.93B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Account

Mackenzie Financial Corp Halozyme Therapeutics, Inc. Transaction History